Specialty Pharmacy Commercialization
Editorial revision: . Original publication and source dates are retained.
Specialty-pharmacy growth must be underwritten at the level of therapy, payer and delivery pathway. Revenue alone cannot establish whether a pharmacy has built a durable business or financed an increasingly expensive flow of prescriptions.
Return to insightsHealthcare founders and operators building regulated revenue assets with payer, provider, and operational complexity. / Evergreen framework
The strategic question
What does a specialty pharmacy build teach about commercializing regulated healthcare assets?
My founder perspective starts with the interaction between access and cash. A referral has limited commercial value if the pharmacy cannot participate in the relevant network, obtain the therapy, resolve authorization and complete a safe dispense. A paid claim has limited economic value if acquisition cost, service intensity and subsequent adjustments consume its contribution. These are linked operating questions, not separate commercial and finance workstreams.
Operating model
Reconcile therapy economics, capacity and cash.
I would build the plan around therapy-level contribution after acquisition cost, contractual adjustments, fulfillment and the professional work required to support the patient. That view should reconcile to payer-level concentration and the timing of cash. A favorable average can hide a growing mix of low-contribution prescriptions or a financing requirement that the balance sheet cannot support.
Inventory is therefore a capital-allocation decision. Additional stock can protect continuity and reduce delay, while tying up cash and creating exposure to expiry, changes in demand and reimbursement uncertainty. The appropriate commitment depends on the therapy, replenishment reliability and the clinical consequences of unavailability. Working capital should be stress-tested against collection delays and changes in purchase terms rather than treated as a fixed percentage of revenue.
Automation should be evaluated against the constraint it can actually remove. Faster fulfillment adds little if authorization or pharmacist review is limiting throughput. A tool that removes a repetitive task may still require verification, maintenance and exception handling. I would assess the effect on safe completed dispensing, staff capacity and cost together, then reflect only realizable changes in the investment case.
Transaction readiness begins with the same operating records needed to run the business: consistent contribution definitions, payer and referral concentration, inventory exposure, quality controls and transferable procedures. The buyer should be able to distinguish recurring operating capability from a founder relationship or a temporary reimbursement advantage. That distinction is central to the durability of the asset and to the terms on which another owner can sustain it.
Operating framework
- 01
Reconcile therapy and payer contribution after acquisition, adjustments, fulfillment and professional support.
- 02
Connect quality controls and accreditation obligations to the cost and capacity of the delivery model.
- 03
Invest in automation where it relieves the constraint on safe, completed dispensing.
- 04
Document payer dependence, inventory exposure and operating procedures that can transfer to a new owner.
Metrics that matter
- 01
Collectible revenue and therapy-level contribution
- 02
Dispensing quality and exception-resolution workload
- 03
Cash tied up in inventory and reimbursement timing
- 04
Payer, therapy and referral-source concentration
Red flags
Prescription growth shifts the mix toward therapies with inadequate contribution or excessive cash requirements.
Service commitments depend on a drug-margin subsidy that disappears under less favorable payer terms.
Fulfillment investment increases throughput while authorization or clinical review remains the limiting capacity.
CEO and CFO questions
How much contribution survives a less favorable payer, therapy or acquisition-cost mix?
Can the balance sheet fund inventory and patient support through a longer collection cycle?
Which capacity investment improves safe dispensing without creating idle assets elsewhere in the pathway?
Discuss the strategic decision